TRUFFLE CAPITAL

G229

Description

Truffle Capital Founded in 2001 by Dr. Philippe Pouletty M.D., Bernard-Louis Roques, Truffle Capital is a leading independent European venture capital firm with €500M in assets under management and over €1.2 billion raised since inception, backing disruptive innovators across BioMedtech and Fintech/Insurtech, with 125 companies financed, 47 exits and 15 IPOs to date. BioMedtech Truffle Capital is a Business Builder in BioMedtech: the firm always acts as founder of its companies, creating them from scratch by sourcing breakthrough science from top universities, structuring the entity, building the management team, and leading the company hands-on from clinical strategy to IPO or M&A exit. This unique model generates decisive control over value creation and timing of exit, delivering exceptional returns for investors. The track record speaks for itself. Truffle founded Abivax in 2013 and led it from inception to dual listing on Euronext and Nasdaq, culminating in a $10Bn+ market cap, a +1,700% stock rally in 2025 and a $750M fundraise (5x oversubscribed) the #2 largest public fundraising ever for a pre-commercial biotech globally, and the only European company in the worldwide top 10 across all sectors. More recently, Truffle created Carvolix in January 2026, reaching a €220M+ market cap (Euronext) with a 4x increase in 6 months and +120% in stock price, ranking #1 European MedTech and #5 worldwide in interventional MedTech among pre-commercial listed companies, the only French company in the global top 10. Building on this proven model, Truffle Capital is currently raising its next dedicated BioMedtech fund, targeting €200 million. Fintech & Insurtech Unlike its BioMedtech approach, Truffle Capital's Fintech strategy focuses on taking equity stakes in existing companies at various growth stages, from early to late stage, in the field of AI, cybersecurity, blockchain and deep tech applied to financial services. The firm acts as lead investor with ticket sizes of €7-15M, takes board seats, and actively supports governance and strategic development. With a strong European footprint across 7 countries and 20 active portfolio companies, Truffle systematically co-invests alongside its LPs to maximize alignment and facilitate exits through IPO, M&A or secondary transactions. As a pioneer and ecosystem builder, Truffle co-created the Fintech100, the leading annual ranking of European software and fintech companies. Truffle is currently launching a new secondary activity, marking a strategic expansion of Truffle's offering to provide investors with additional liquidity solutions.